AI-Designed 'Universal' Coronavirus Vaccine Passes First Human Trial, Showing Safety but Modest Immune Response
Cambridge spin-out DIOSynVax's pEVAC-PS, the first vaccine whose active ingredient was designed entirely by computer, proved safe in 39 volunteers but produced only modest immunity.
Overview
A vaccine whose active ingredient was designed entirely by computer has passed its first test in humans, according to the University of Cambridge. The candidate, called pEVAC-PS, was given to 39 healthy volunteers in a Phase 1 trial and proved safe with no significant side-effects, but the immune responses it generated were modest, results published in the Journal of Infection show.
The vaccine was developed by the University of Cambridge and its spin-out company DIOSynVax (DVX) Ltd, the university said. Its developers describe it as a “universal” shot intended to protect against an entire family of coronaviruses rather than a single strain, an approach aimed at the kind of viruses that have repeatedly spilled over from animals into humans.
What We Know
The trial enrolled 39 healthy volunteers and tested the vaccine in a Phase 1 study, according to ScienceDaily, which reproduced the Cambridge announcement. The participants were adults aged 18 to 50, as reported by Interesting Engineering.
What distinguishes pEVAC-PS is how its target was created. Rather than copying a protein from a circulating virus, researchers used machine learning to analyze all available genetic sequence data for Sarbeco coronaviruses and combine the features shared across the group into a single engineered antigen, according to the University of Cambridge. The Cambridge team describes the result as an AI-designed “super-antigen” and says it is the first vaccine whose active component was designed entirely by computer simulations. The design is meant to focus the immune system on the parts of the coronavirus that stay largely the same across many different variants, according to StudyFinds.
The candidate is a DNA plasmid-based, needle-free vaccine, as reported by pharmaphorum. It is delivered through a needle-free microfluidic jet system, according to Interesting Engineering.
On safety, the picture was clear. The vaccine “is safe and has no significant side-effects,” the University of Cambridge reported. No serious adverse reactions occurred, and the vaccine was well tolerated across all four dose levels tested, according to StudyFinds.
The vaccine also triggered immune responses not only to SARS-CoV-2 and SARS, but to related bat viruses, according to News-Medical. The trial was primarily funded by Innovate UK, as reported by Interesting Engineering.
Professor Jonathan Heeney, of Cambridge’s Lab of Viral Zoonotics, framed the platform as a shift in how vaccines are made. “We’ve converted vaccine development from being reactive to being future proof,” Heeney said, according to the University of Cambridge. Professor Saul Faust of the University of Southampton, the trial’s chief investigator, said “This new class of universal vaccines are future-proofed,” according to ScienceDaily.
What We Don’t Know
The results stop well short of demonstrating that pEVAC-PS would actually protect people. The vaccine’s immunogenicity was “modest but variable,” and the candidate has not shown “broad or robust neutralising activity,” according to pharmaphorum. Antibody levels were modest across the board, and the magnitude fell short of the strong, dose-dependent rise researchers would ideally want to see, according to StudyFinds.
As an early-stage Phase 1 trial, the study was designed to gauge safety and whether the immune system responds to the right targets, not to prove efficacy. Whether the modest responses can be strengthened, and whether they would translate into real-world protection, remains unresolved.
To address that, a larger Phase 2 trial is planned to assess the vaccine’s ability to induce immune responses in a wider and more diverse population, according to the University of Cambridge.
Analysis
The headline development here is less the vaccine itself than the design method behind it. Conventional vaccines are reactive: developers wait for a pathogen to emerge, then build a shot matched to it, a cycle that leaves new strains poorly matched by the time vaccines reach the public, as Faust noted to pharmaphorum. A computationally designed antigen aimed at conserved features of a whole viral family is an attempt to break that cycle.
But the trial is a reminder that a clever target is only half the problem. Proving an antigen is safe and reaches the right parts of the virus is a meaningful first step; generating strong, durable, broadly neutralising immunity is a much higher bar, and the modest responses reported here show how far the candidate still has to go before it could become a deployable universal vaccine.